DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
08 November 2022 - 12:32AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company focused on developing novel treatments
for neurological disorders and kidney diseases, today announced
that Rick Pauls, its President and CEO will be participating in the
13th Annual Craig-Hallum Alpha Select Conference being held in New
York on Thursday, November 17, 2022.
Investors and attendees that would like to schedule a meeting
with DiaMedica’s management can contact their Craig-Hallum
representative to arrange a meeting.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases. DiaMedica’s lead candidate
DM199 is the first pharmaceutically active recombinant (synthetic)
form of the KLK1 protein, an established therapeutic modality for
the treatment of acute ischemic stroke and chronic kidney disease.
For more information visit the Company’s website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005660/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From Apr 2024 to May 2024
DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From May 2023 to May 2024